Coronary Atherosclerosis Assessment by Coronary CT Angiography in Asymptomatic Diabetic Population: A Critical Systematic Review of the Literature and Future Perspectives

Andrea Igoren Guaricci, Delia De Santis, Mariangela Carbone, Giuseppe Muscogiuri, Marco Guglielmo, Andrea Baggiano, Gaetano Serviddio, and Gianluca Pontone

1 Institute of Cardiovascular Disease, Department of Emergency and Organ Transplantation, University Hospital Policlinico of Bari, Bari, Italy
2 Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy
3 Section of Diagnostic Imaging, Interdisciplinary Department of Medicine, University Hospital Policlinico of Bari, Bari, Italy
4 Centro Cardiologico Monzino, IRCCS, Milano, Italy
5 CMO Torre Annunziata, Napoli, Italy

Correspondence should be addressed to Gianluca Pontone; gianluca.pontone@ccfm.it

Received 30 June 2017; Accepted 2 December 2017; Published 15 January 2018

Academic Editor: Charbel Abi Khalil

Copyright © 2018 Andrea Igoren Guaricci et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The prognostic impact of diabetes mellitus (DM) on cardiovascular outcomes is well known. As a consequence of previous studies showing the high incidence of coronary artery disease (CAD) in diabetic patients and the relatively poor outcome compared to nondiabetic populations, DM is considered as CAD equivalent which means that diabetic patients are labeled as asymptomatic individuals at high cardiovascular risk. Lessons learned from the analysis of prognostic studies over the past decade have challenged this dogma and now support the idea that diabetic population is not uniformly distributed in the highest risk box. Detecting CAD in asymptomatic high risk individuals is controversial and, what is more, in patients with diabetes is challenging, and that is why the reliability of traditional cardiac stress tests for detecting myocardial ischemia is limited. Cardiac computed tomography angiography (CCTA) represents an emerging noninvasive technique able to explore the atherosclerotic involvement of the coronary arteries and, thus, to distinguish different risk categories tailoring this evaluation on each patient. The aim of the review is to provide a wide overview on the clinical meaning of CCTA in this field and to integrate the anatomical information with a reliable therapeutic approach.

1. Introduction

Diabetes mellitus (DM) is a major public health problem, the incidence of which seems to be drastically increased and will grow in the next years [1, 2]. Many studies in the literature showed a clear correlation between DM and risk of coronary heart disease (CAD) [3–5]. Moreover, compared with matched nondiabetic individuals, patients with diabetes has a higher prevalence, extent, and severity of CAD [6]. On the basis of these considerations and on the beneficial removal of the risk factors on progression of atherosclerotic disease, early detection of diabetic patients at increased risk of adverse cardiac events is crucial.

Coronary computed tomography angiography (CCTA) is an emerging noninvasive technique for the evaluation of coronary stenosis and for the characterization of the atherosclerotic plaques [7–9]. However, although the diagnostic accuracy and prognostic value of CCTA have been largely proved in symptomatic low-intermediate patients [10–13], its role in the asymptomatic and diabetic individuals is still widely debated [14, 15]. The American Diabetes Association and American Heart Association recently issued a
joint statement that urges the identification of asymptomatic patients with subclinical CAD in whom more aggressive lifestyle or treatment changes would allow prevention of progression of the disease and reduce future clinical events [16]. In the light of this, the objective of our review is to assess the rationale and effectiveness of CAD screening in asymptomatic diabetic patients by CCTA, providing future perspectives on potentiality of this emerging noninvasive imaging technique.

2. Diabetes Mellitus as Coronary Risk Equivalent: An Unsolved Matter

CAD represents the main cause of mortality and morbidity in patients affected by DM, which was considered as a "coronary risk" equivalent [17, 18]. The validated correlation between DM and increased risk of CAD sparked a vivacious debate in the scientific community about the appropriateness of considering the diabetics as patients affected by CAD by default. The consideration of the DM as a "coronary equivalent," however, has a remarkable role because it implies a very aggressive treatment with significant healthcare costs, possible lack of patient's compliance, and risk of adverse effects.

In order to weigh up the risk of CAD in the diabetic population compared to nondiabetic population, Haffner et al. [19] compared the incidence of AMI in 1373 diabetic patients and 1059 nondiabetic subjects in the Finnish population and followed them up for 7 years. The study showed that previous AMI had a substantial role in determination of second AMI, stroke, and cardiovascular death. AMI incidence in nondiabetic population was 18.8% in the population with prior AMI and, conversely, 3.5% in nondiabetic population without prior AMI. In parallel, in diabetes group, the incidence of AMI was 45.0% in the population with prior AMI and 20.2% in the population without prior AMI. On the other hand, nondiabetic patients without previous AMI showed better survival. The substantial novelty of the study is finding a similar incidence of cardiovascular events in the group of 890 patients with DM without prior AMI and in the group of 69 patients without DM but with prior AMI, in a follow-up of 7 years. This correlation is unchanged even after adjustment for demographic variables (age and gender) and other cardiovascular risk factors (smoking, hypertension, lipid profile). On the basis of these results, the authors affirmed the negative impact of DM on coronary perfusion because diabetic patients with no known history of CAD presented the same risk of cardiovascular death as patients without DM but with prior AMI. For this reason, Haffner considered DM as an equivalent of CAD, implying an increase of 20% in the 10-year cardiovascular risk of adverse events. This result suggests and encourages the treatment of all diabetic patients, as if they were really affected by known CAD [20]. Although recent studies confirmed and supported the consideration of "coronary risk equivalency" [21, 22], other bodies of evidence seem to reconsider this assumption, suggesting the identification of different classes of risk [23, 24]. A meta-analysis published in 2009 [25] compared the total risk of coronary events in diabetic patients without previous AMI and nondiabetic patients with previous AMI. This meta-analysis evaluated 13 studies including 45,108 patients with a mean follow-up of 13.4 years and a mean age of the enrolled subjects between 25 and 84 years. 2603 CHD events were found in diabetic population with no previous AMI; on the other hand, 3927 events were recorded in the nondiabetic population with prior AMI. This work showed that diabetic patients without previous AMI presented a 43% lower risk of developing coronary events compared with nondiabetic patients with prior AMI (summary odds ratio 0.56, 95% confidence interval 0.53–0.60). This result suggests that, although DM is an important risk factor for the development of cardiovascular adverse events, it cannot be considered as a "coronary risk equivalent." Recently, Rana et al. [26] have studied a large cohort of 1,586,081 adults, admitted to the Kaiser Permanente Northern California healthcare system, aged between 30 and 90 years with a 10-year follow-up. The study compared the risk of adverse cardiac events in the population divided into 4 groups according to the presence of DM and coronary heart disease (CHD). The study confirmed that the sole presence of prior CHD is associated with an almost twofold increased risk of CHD compared to the presence of sole DM (12.2 versus 22.5 per 1000 person-years), suggesting that the DM is an additional risk factor rather than a trigger in the progression of CAD. Remarkably, only when diabetes was present for more than 10 years, the risk of future CHD for patients with diabetes was similar to that for those with previous CHD. Of note is that, although the Adult Treatment Panel (ATP) III guidelines in 2001 recommended lifestyle and therapeutic primary prevention in diabetics [20], subsequent ACC/AHA American guidelines on the individual risk assessment reduced the DM role in the progression of atherosclerotic disease, on the basis of these new scientific bodies of evidence in the literature [27]. Therefore, there is no scientific evidence to support an aggressive therapeutic strategy with statins and aspirin in all patients with DM, but only in diabetic patients at high risk, in order to reduce cardiovascular mortality. On the basis of this important meta-analysis, it is crucial and essential to identify diabetic patients at high risk of adverse coronary events, worthy of an adequate aggressive therapy with statins and aspirin.

3. Standard Diagnostic Approach to Asymptomatic Diabetic Patient

In view of the high prevalence of CAD and the nonnegligible autopsy rates of silent coronary ischemia in diabetic patients due to prevalent neuropathy [28], noninvasive stress imaging could be useful in the prognostic stratification of asymptomatic diabetic patients in order to minimize vascular consequences of chronic hyperglycemia and optimize therapeutic approach.

Detecting CAD in patients with diabetes is challenging [29]. The involvement of small vessels due to metabolic abnormalities and the diffuse nature of the disease limit the reliability of cardiac stress tests for detecting myocardial ischemia [17], further worsened by the comorbidities (Figure 1). In addition, the silent fashion of CAD due to previous AMI was 45.0% in the population with prior AMI and 20.2% in the population without prior AMI. In parallel, in diabetes group, the incidence of AMI was 45.0% in the population with prior AMI and 20.2% in the population without prior AMI. On the other hand, nondiabetic patients without previous AMI showed better survival. The substantial novelty of the study is finding a similar incidence of cardiovascular events in the group of 890 patients with DM without prior AMI and in the group of 69 patients without DM but with prior AMI, in a follow-up of 7 years. This correlation is unchanged even after adjustment for demographic variables (age and gender) and other cardiovascular risk factors (smoking, hypertension, lipid profile). On the basis of these results, the authors affirmed the negative impact of DM on coronary perfusion because diabetic patients with no known history of CAD presented the same risk of cardiovascular death as patients without DM but with prior AMI. For this reason, Haffner considered DM as an equivalent of CAD, implying an increase of 20% in the 10-year cardiovascular risk of adverse events. This result suggests and encourages the treatment of all diabetic patients, as if they were really affected by known CAD [20]. Although recent studies confirmed and supported the consideration of "coronary risk equivalency" [21, 22], other bodies of evidence seem to reconsider this assumption, suggesting the identification of different classes of risk [23, 24]. A meta-analysis published in 2009 [25] compared the total risk of coronary events in diabetic patients without previous AMI and nondiabetic patients with previous AMI. This meta-analysis evaluated 13 studies including 45,108 patients with a mean follow-up of 13.4 years and a mean age of the enrolled subjects between 25 and 84 years. 2603 CHD events were found in diabetic population with no previous AMI; on the other hand, 3927 events were recorded in the nondiabetic population with prior AMI. This work showed that diabetic patients without previous AMI presented a 43% lower risk of developing coronary events compared with nondiabetic patients with prior AMI (summary odds ratio 0.56, 95% confidence interval 0.53–0.60). This result suggests that, although DM is an important risk factor for the development of cardiovascular adverse events, it cannot be considered as a "coronary risk equivalent." Recently, Rana et al. [26] have studied a large cohort of 1,586,081 adults, admitted to the Kaiser Permanente Northern California healthcare system, aged between 30 and 90 years with a 10-year follow-up. The study compared the risk of adverse cardiac events in the population divided into 4 groups according to the presence of DM and coronary heart disease (CHD). The study confirmed that the sole presence of prior CHD is associated with an almost twofold increased risk of CHD compared to the presence of sole DM (12.2 versus 22.5 per 1000 person-years), suggesting that the DM is an additional risk factor rather than a trigger in the progression of CAD. Remarkably, only when diabetes was present for more than 10 years, the risk of future CHD for patients with diabetes was similar to that for those with previous CHD. Of note is that, although the Adult Treatment Panel (ATP) III guidelines in 2001 recommended lifestyle and therapeutic primary prevention in diabetics [20], subsequent ACC/AHA American guidelines on the individual risk assessment reduced the DM role in the progression of atherosclerotic disease, on the basis of these new scientific bodies of evidence in the literature [27]. Therefore, there is no scientific evidence to support an aggressive therapeutic strategy with statins and aspirin in all patients with DM, but only in diabetic patients at high risk, in order to reduce cardiovascular mortality. On the basis of this important meta-analysis, it is crucial and essential to identify diabetic patients at high risk of adverse coronary events, worthy of an adequate aggressive therapy with statins and aspirin.

3. Standard Diagnostic Approach to Asymptomatic Diabetic Patient

In view of the high prevalence of CAD and the nonnegligible autopsy rates of silent coronary ischemia in diabetic patients due to prevalent neuropathy [28], noninvasive stress imaging could be useful in the prognostic stratification of asymptomatic diabetic patients in order to minimize vascular consequences of chronic hyperglycemia and optimize therapeutic approach.

Detecting CAD in patients with diabetes is challenging [29]. The involvement of small vessels due to metabolic abnormalities and the diffuse nature of the disease limit the reliability of cardiac stress tests for detecting myocardial ischemia [17], further worsened by the comorbidities (Figure 1). In addition, the silent fashion of CAD due to high threshold for pain reduces the sensitivity of clinical risk assessment [30].
Figure 1: Dobutamine stress echocardiography in patient affected by diabetes mellitus (DM) with chronic pulmonary obstructive disease (COPD) and poor acoustic window. (a) Apical four-chamber view of left ventricle. (b) The use of ultrasound contrast agent definitively allows an acceptable imaging quality of the endocardial border. (c) 3D heart model is imaged. It represents a chamber quantification using a model-based segmentation algorithm for achieving a more accurate functional assessment.

Exercise electrocardiography (EKG) is the most used noninvasive technique for the diagnostic and prognostic evaluation of nondiabetic patients with known or suspected CAD. Unfortunately, the accuracy of exercise EKG is reduced in the diabetic population. The poor response in terms of pressure and heart rate increasing during exercise, the high incidence of silent myocardial ischemia and microvascular disease, the alterations of impulse conduction due to visceral neuropathy, the presence of baseline ST-segment abnormalities, left ventricular hypertrophy, and the impaired exercise capacity due to peripheral vascular disease limited the diagnostic and prognostic value of exercise EKG. Given the limited accuracy of exercise EKG stress in diabetic patients, myocardial stress imaging tests have been proposed [31] also thanks to their ability to identify changes in regional contractility depending on the location and size of the ischemic area. In asymptomatic diabetic patients, the sensitivity and specificity of stress echocardiography in the diagnosis of CAD are reported to be 81% and 85%, respectively [32].

Stress echocardiography allows identifying, in the absence of signs of stress ischemia, patients at low risk of developing adverse cardiac events [33, 34]. Two studies conducted on diabetic sample revealed a small number of false negatives in the identification of CAD, sustaining good efficacy of stress echocardiography in identifying low risk diabetic patients to develop cardiac events [35, 36]. Few years later, Kamalesh et al. [37] studied the incidence of adverse cardiac events in a diabetic and nondiabetic population with absence of signs of inducible ischemia as assessed by stress echocardiography and followed them up for 25 ± 7 months. The study showed that diabetic patients, compared to nondiabetic ones, had a higher incidence of cardiac events (19% versus 9.7%, \( p = 0.03 \)), worse event-free survival (\( p = 0.03 \)), and a greater number of nonfatal MI events (6.7% versus 1.4%, \( p < 0.05 \)). The study revealed also that the history of CAD was the only predictor of adverse cardiac events (\( R = 0.18, p < 0.05 \)). On the basis of these results, Kamalesh concluded that diabetic patients with negative stress echocardiogram have more risk for adverse cardiac events compared to nondiabetic patients. The cause of this substantial difference could be explained by the greater tendency of diabetic patients to have distal CAD, slightly detectable by stress echocardiography. Moreover, diabetic patient presents an alteration of the coagulation pattern, intense platelet activity, and reduced fibrinolysis which, together with the recognized autonomic dysfunction, most frequently predispose the patient to coronary occlusion [38]. On the same line, Cortigiani et al. [39] showed that a negative, nonischemic stress test in the diabetic population, particularly in the subset of patients aged >65 years, is associated with an increased risk of developing adverse cardiac events when compared to nondiabetic subjects of the same age. Confirming these results, other studies showed an annual incidence of adverse cardiac events in diabetic patients with normal stress test equal to 3–6%, about twice that in nondiabetic patients with normal stress test [40, 41]. On the other hand, some large studies assessed the prognostic value of single-photon emission computed tomography imaging in patients with DM and, importantly, also in this scenario the event rate was higher compared with the control population, even in presence of a normal scan [29, 42].

On the basis of these considerations, although exercise stress testing and myocardial perfusion imaging remain important techniques for risk assessment and prognosis of CAD in asymptomatic diabetic patients, presence of confounding factors, such as autonomic dysfunction, multivessel disease, EKG abnormalities and interpretative difficulties, peripheral artery disease, and the need for polypharmacy, could compromise the diagnostic efficacy explaining why their role remains controversial [43].

4. Calcium Scoring

Coronary artery calcium score (CACS) is widely considered a marker of subclinical atherosclerosis, validated in asymptomatic patients [47]. Extent of CACS, in fact, well correlates with the vascular atherosclerotic involvement and the probability of adverse cardiac events in the general population [48–50]. Although the latest European guidelines on cardiovascular prevention [51] suggested evaluation of
the CACS only in diabetic patients with high or very high cardiovascular risk (score > 5% and score > 10%), the latest American guidelines for risk stratification in patients with CAD recommended an “appropriate” use of CACS and CCTA in asymptomatic patients with high global risk [52].

Type 2 DM patients have higher values of CACS when compared with the general population [53]. The mechanisms responsible for the extensive intracoronary calcium accumulation in diabetic patients are multifactorial and not completely understood. Previous studies revealed that the increased production of advanced glycation end-products induces the overexpression of genes and enzymes involved in active calcification of the coronary plaque [54]. Coronary artery calcium scoring (CACS) has been proposed as a first-line test for CAD in patients with diabetes [55] since it was widely demonstrated that it has higher capability with respect to conventional cardiovascular risk factors for predicting silent myocardial ischemia and short-term outcome [56]. Numerous studies showed that higher values of CACS in diabetic patients with metabolic syndrome are closely associated with increased prevalence of ischemia, adverse cardiac events, AMI, and mortality [57–60].

Notwithstanding, a significant percentage of patients with DM have very low or zero CACS, with a better long-term prognosis, revealing that DM is not an equivalent of coronary risk. Raggi et al. documented a high proportion of asymptomatic patients with DM (39%) with CACS < 10 [61]. In this study the authors confirmed a significant correlation between CACS and DM (p = 0.00001), indicating that each increase of CACS correlates with an increase in mortality in diabetic and nondiabetic patients. However, diabetic patients without known CAD showed similar survival to patients without DM and intracoronary calcium (98.8% and 99.4%, resp., p: 0.5). The results of other studies show the same trend [62, 63].

5. Coronary Computed Tomography Angiography (CCTA)

Recently, CCTA has emerged as a reliable noninvasive imaging tool for the identification of CAD [64–68]. Since is first steps, the technique has been characterized by a very high negative predictive value, whereas the positive predictive value has been growing progressively, mainly according to the improvement of many technical aspects [69]. The suboptimal positive predictive value and specificity of CCTA in assessing the coronary stenosis degree are mostly due to the “blooming” artifacts secondary to the presence of wall calcifications. In particular, the coronary arteries in diabetic subject are characteristically “small and calcific,” and this explains why the specificity of CCTA in this specific subset of patients may be particularly low (Figure 2). At the same time, the technological innovation has been taking a giant step towards the artifacts reduction by implementing different strategies throughout the process, from the premedication of the patient before scanning to the acquisition and analysis of the images [70–74]. Of note is that a new important and very attractive tool able to evaluate the functional value of a single stenosis, the fractional flow reserve CT (FFR_{CT}), is not influenced by the presence of calcifications and thus is particularly reliable in diabetic population (Figure 3) [75–79]. Among all others, the employment of high definition techniques [80] allows high values of specificity and diagnostic accuracy (close to 90% and 95–98%, resp.).
Pivotal information is obtained by CCTA, specifically that obstructive and nonobstructive CAD are characterized by a higher prevalence in the diabetic population compared to normoglycemic patients and that a different plaque composition does exist [81–83]. Table 1 shows as a whole that among patients with DM, nonobstructive and obstructive CAD according to CCTA are associated with higher rates of all-cause mortality and major adverse cardiovascular events at follow-up, and this risk is significantly higher than that in nondiabetic subjects. Despite this, current European guidelines do not advise coronary CTA for risk assessment and suggest other noninvasive testing methods (nuclear imaging, echocardiography, and carotid ultrasound) in high risk diabetic patients [84]. Conversely, the latest American guidelines for detection and risk assessment of stable CAD state that calcium scoring and coronary CTA use “may be appropriate” in asymptomatic patients with high global risk [52, 85].

The fulcrum of noninvasive coronary assessment in diabetic population consists in its prognostic value. Numerous efforts have been made so far in order to add useful information on this debated topic.
Table 1: Randomized studies that investigated the prognostic power of CCTA in asymptomatic or stable patients with diabetic mellitus versus nondiabetics.

| Authors/journal | Diabetics | Nondiabetics | Follow-up | Events in diabetics | Events in nondiabetics | Characteristic of CAD at CCTA | Univariate analysis in diabetics (HR) | Multivariate analysis in diabetics (HR) | Univariate analysis in nondiabetics (HR) | Multivariate analysis in nondiabetics (HR) |
|-----------------|-----------|--------------|-----------|---------------------|------------------------|-----------------------------|---------------------------------------|----------------------------------------|------------------------------------------|------------------------------------------|
| Van Werkhoven et al./Radiology 2010 [44] | n = 313 | n = 303 | 20 ± 5.4 months | Total cardiac events (88) | Total cardiac events (45) | p < 0.001 | Obstructive 6.57 (p < 0.001) | 16.29 (p < 0.001) | 21.64 (p < 0.001) |
| Rana et al./Diabetes Care 2012 [6] | n = 3370 | n = 6740 | 26 months | Death n = 108 (3.2%) | Death n = 115 (1.7%) | | Nonobstructive (1) Vessel disease | 5.25 | 3.12 (p < 0.01) |
| | | | | | | | (2) Vessel disease | 6.39 | 5.56 (p < 0.01) |
| | | | | | | | (3) Vessel disease | 12.33 | 7.87 (p < 0.01) |
| | | | | | | | | | | 13.25 | 9.25 (p < 0.01) |
| Nadjiriet et al./Int J Cardiovasc Imag 2015 [45] | n = 108 | n = 1379 | 66 ± 12.2 months | Cardiac events N = 10 (annual cardiac event rate 1.7%) | Number of lesions per patient (SIS) | | 3.0 (p = 0.047) | | |
| | | | | | | | Segments stenosis score (SSS) | 4.5 (p = 0.025) | | |
| | | | | | | | Cardiac events N = 48 (annual cardiac event rate 0.64%) | Number of lesions per patient (SIS) | 1.31 (p = 0.076) | | |
| | | | | | | | Segments stenosis score (SSS) | 1.3 (p = 0.062) | | |
| Blanke et al./Jacc CI 2016 [46] | n = 1823 | n = 1823 | 60 months | Death n = 246 (13.5%) | Death n = 136 (7.5%) | | Nonobstructive (1) Vessel disease | 2.09 (p < 0.001) | 1.95 (p < 0.001) |
| | | | | | | | (2) Vessel disease | 1.48 (p = 0.08) | |
| | | | | | | | (3) Vessel disease | 2.45 (p = 0.003) | |
| | | | | | | | | | | 2.31 (p = 0.002) | |

CAD: coronary artery disease; CCTA: coronary computed tomography angiography; HR: hazard ratio; RR: relative risk.

RR for all-cause mortality in diabetics compared with propensity matched nondiabetics stratified according to extent/severity of CAD
Min et al. [86] evaluated the prognostic value of CCTA in a population of 400 asymptomatic diabetic patients without known history of CAD. This study showed that, after adjustment for CAD risk factors, the maximum stenosis, the number of coronary arteries involved, and the segment stenosis score are associated with increased risk of developing adverse cardiac events and had incremental power for predicting cardiac events over conventional risk factors. Moreover, the study revealed that CCTA confers incremental risk prediction, discrimination, and reclassification over CACS. Based on these results, CCTA seems to be very useful in risk stratification of asymptomatic diabetic patients at higher risk of developing adverse cardiac events. Halon et al. [87] examined the added value of CCTA over clinical risk scores of United Kingdom Prospective Diabetes Study (UKPDS) and coronary artery calcium in a population based cohort of 630 asymptomatic type 2 diabetics with no history of CAD assessed for coronary heart disease related events over 6.6 ± 0.6 years. Discrimination of all events was improved by addition of total plaque burden to the clinical risk and CACS combined and further improved by addition of an angiographic score.

Van Werkhoven et al. [44] confirmed the usefulness of CCTA in prognostic stratification of diabetic patients (N = 313) with known or suspected CAD compared to nondiabetic patients (N = 303). Authors found that DM (p < 0.001) and evidence of obstructive CAD (>50% coronary stenosis) (p < 0.001) were independent predictors of outcome. In particular and similarly to other bodies of evidence [88, 89], the presence of obstructive CAD is an important predictor of survival both in diabetic patients and in nondiabetic patients. Conversely, absence of atherosclerosis in CCTA is associated with excellent (100%) disease-free survival at a mean follow-up of 20 ± 5.4 months, confirming the known high predictive value of CT both in diabetic and in nondiabetic patients [90, 91].

Furthermore, the study conducted by Kim et al. [92] demonstrated that the duration of DM is significantly associated with the extent and the severity of CAD. Patients with a longer history of DM had higher levels of CACS, atheroma burden obstructive score, segment involvement score, and segment stenosis score (p < 0.001 for all). In addition, the severity of coronary stenosis clearly increases the incidence of adverse cardiac events, independently of other cardiovascular risk factors. On the basis of these considerations, authors suggest the introduction of CCTA screening in all patients with a history of DM > 10 years.

On the contrary, the study of Muhlestein et al. revealed that the use of CCTA as screening of asymptomatic diabetic patients did not reduce the incidence of mortality from all causes and nonfatal myocardial infarction. However, the value of this result could be resized taking into consideration the low incidence of adverse cardiac events in the study which reduces the statistical difference between the two groups [93]. Other than being underpowered, the study was biased by the fact that adequate care targets for risk factor reduction in most of patients assigned to receive aggressive therapy in CCTA group were not achieved. Moreover, the control group without CTA scanning also received good preventive medical treatment so that differences in therapy between the screened and nonscreened groups were subtle.

Recently, Kang et al. confirmed the prognostic value in long term of CCTA in a population of asymptomatic diabetics [94]. This study analyzed clinical outcome of 591 asymptomatic patients with type 2 DM undergoing CCTA showing that the survival free of cardiac events was 99.3 ± 0.7% in patients with normal coronary arteries, 96.7 ± 1.2% in those with nonobstructive CAD, and 86.2 ± 3.0% in those with obstructive CAD (log-rank p < 0.001). The present study confirmed that asymptomatic diabetic patients with normal coronary arteries or with nonobstructive CAD have an excellent clinical outcome even after five years, conversely to patients with obstructive CAD. An overview is given by a recent meta-analysis based on eight studies with a total of 6225 participants (56% male with average age of 61 years) and a mean follow-up of 20 to 66 months that evaluated the prognostic efficacy of CCTA in diabetic patients [95]. This meta-analysis concluded that CCTA is critical in identifying diabetic patients at high risk of CAD to be assigned to an aggressive modification of risk factors, glycemic control, and optimized medical therapy.

6. Therapeutic Perspectives

At this point it is not incorrect to say that CCTA is able to distinguish between high and low risk diabetics patients, unveiling the presence of severe CAD. At the same time, CCTA can detail anatomic information of CAD features providing incremental power in the context of primary prevention of acute cardiac events [96]. The ability of this technique in revealing some vulnerability features of coronary plaque is known, including positive remodelling, presence of large plaque burden, and spotty calcification which increase the probability of plaque rupture and complication. Sometimes the “anatomic” high risk condition coexists in a “systemic” vulnerable context depicted by DM and kindled inflammatory state [97, 98] (Figure 4). A recent study [98] reported that diabetic subjects with increasing circulation levels of interleukins-6 and carotid artery disease had high probability of obstructive CAD and high risk plaques. Notwithstanding, the CV risk of the diabetic population is not uniform, and the vital and decisive pivot of the right identification of high risk subset of diabetics consists in impact on prophylactic therapy. The European Society of Cardiology guidelines recommend the consideration of aspirin use for primary prevention in patients at high risk with DM [17], while the Endocrine Society Clinical Practice guidelines recommend aspirin in patients with DM aged > 40 years and whose 10-year CV disease risk is more than 10% [99]. Moreover, the existing risk charts tailored on patients with DM, such as the United Kingdom Prospective Diabetes Study and the Swedish National Diabetes Register [100, 101], need further validation for clinical applicability. Although noninvasive imaging tests demonstrated their value in risk stratification of diabetic subjects [102], no mention is made of the need for incorporating them in the diagnostic flow charts.

In a valuable attempt to correlate traditional CV risk factors with anatomic CAD features, Dimitriu-Leen et al. [103]
prospectively studied a large asymptomatic diabetic population at high risk. On CCTA, 27% of these patients had no CAD. Considering patients with any CAD (73%), around half had obstructive CAD (more than 50% stenosis). Importantly, the study showed that the number and presence of risk factors were not associated with a higher frequency of CAD, except for hypertension. As a consequence, the authors underlined that CCTA could be pivotal in identifying which patients will benefit most from prophylactic prevention with aspirin. In this regard, it is necessary to keep in mind that aspirin is only useful if coronary atherosclerosis is present [104]. Notably, screening patients according to their CACS instead of exploring CAD on CCTA would result in undertreatment of 9% (diabetics with obstructive CAD) to 36% (diabetics with any CAD) of patients at high risk with DM who may benefit from therapy and this is in line with what other authors have shown [105]. The importance of well defining the high risk diabetic subjects worthy of prophylactic aspirin therapy derives from the evidence that the trials aimed at establishing its beneficial effect have been controversial and, particularly, 2 of those have failed in demonstrating significant reductions in CV events [106, 107]. Taylor et al. [108] in their analysis revealed the poor utility of statins use in diabetic population. This result, apparently paradoxical, highlights that diabetic patient should not necessarily be considered as a “coronaric” patient to be subjected to intensive medical therapy. Diabetic patients, in fact, in the presence of CACS < 10, have a brilliant prognosis, comparable with nondiabetic patients. Moreover, a substudy of the “coronary CT angiography evaluation for clinical outcomes: an international multicenter (CONFIRM) international registry” demonstrated in 4,706 patients with nonobstructive (less than 50% stenosis) CAD that prophylactic aspirin use was not associated with an improvement in all-cause mortality.

Although these bodies of evidence aim to demonstrate a rationale employment of prophylactic therapy, it seems
clear that more comprehensive prospective studies, including inflammatory biomarker and polyvascularity assessment together with preventive treatment strategies, are warranted.

7. Conclusions

There is marked heterogeneity of risk among diabetic patients which has recently gained by scientific community. Clinical risk assessment, standard noninvasive imaging techniques, and CACS alone lack very accurate and tailored risk stratification at single level patient. Coronary computed tomography angiography represents a new technique able to detail CAD features providing diagnostic and prognostic information on asymptomatic type 2 diabetics. The direct consequences of this are that a significant proportion with no or very little coronary plaque are at negligible risk and others with more extensive plaque at considerably higher risk for an acute coronary event. Moreover, the prognostic prediction is refined with the consideration of plaque composition and with the assessment of inflammatory/polyvascular systemic involvement. In diabetics at low risk, the intensity of preventive medical therapy and frequency of follow-up may be reduced, particularly when there is intolerance to aspirin and high doses of statins or other prophylactic therapies. Afterwards, a stepwise approach of screening on the basis of cardiovascular risk factors and global clinical risk would allow characterization of a higher-risk group in which CACS followed by CTA is able to further risk stratification. In the setting of patients with more than 10 years of disease, a direct anatomical imaging strategy may allow the quick and reliable risk stratification of each patient. The identification of significant CAD in the context of a patient with DM could justify an intensive preventive regimen based on aspirin and, accordingly, on clinical conditions, statins, and antihypertensive drugs.

Disclosure

Dr. Gianluca Pontone received institutional grant and fee from GE Healthcare, Medtronic, Bracco, and Heartflow.

Conflicts of Interest

The authors declare that they have no relationship with industry or financial associations within the past 2 years which poses conflicts of interest in connection with the submitted article.

References

[1] K. M. V. Narayan, J. P. Boyle, L. S. Geiss, J. B. Saaddine, and T. J. Thompson, "Impact of recent increase in incidence on future diabetes burden: U.S., 2005–2050," *Diabetes Care*, vol. 29, no. 9, pp. 2114–2116, 2006.

[2] H. King, R. E. Aubert, and W. H. Herman, "Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections," *Diabetes Care*, vol. 21, no. 9, pp. 1414–1431, 1998.

[3] D. M. Nathan, J. Meigs, and D. E. Singer, "The epidemiology of cardiovascular disease in type 2 diabetes mellitus: how sweet it is… or is it?" *The Lancet*, vol. 350, no. 1, pp. 4–9, 1997.

[4] W. B. Kannel and D. L. McGee, "Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study," *Diabetes Care*, vol. 2, no. 2, pp. 120–126, 1979.

[5] N. Sarwar, P. Gao, and S. R. Seshasai, "Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies," *The Lancet*, vol. 375, no. 9733, pp. 2215–2222, 2010.

[6] J. S. Rana, A. Dunning, S. Achenbach et al., "Differences in prevalence, extent, severity, and prognosis of coronary artery disease among patients with and without diabetes undergoing coronary computed tomography angiography: results from 10,110 individuals from the CONFIRM (Coronary CT Angiography Evaluation for Clinical Outcomes): an InteRnational Multicenter Registry," *Diabetes Care*, vol. 35, no. 8, pp. 1787–1794, 2012.

[7] E. Maffei, C. Martini, C. Tedeschi et al., "Diagnostic accuracy of 64-slice computed tomography coronary angiography in a large population of patients without revascularisation: registry data on the comparison between male and female population," *La Radiologia Medica*, vol. 117, no. 1, pp. 6–18, 2012.

[8] G. Pontone, D. Andreini, A. I. Guaricci et al., "The STRATEGY Study (Stress Cardiac Magnetic Resonance Versus Computed Tomography Coronary Angiography for the Management of Symptomatic Revascularized Patients): resources and Outcomes Impact," *Circulation: Cardiovascular Imaging*, vol. 9, no. 10, Article ID 005171, 2016.

[9] G. Pontone, M. G. Rabbat, and A. I. Guaricci, "Stress Computed Tomographic Perfusion," *Circulation: Cardiovascular Imaging*, vol. 10, no. 4, p. e006324, 2017.

[10] A. I. Guaricci, G. Pontone, N. D. Brunetti et al., "The presence of remodeled and mixed atherosclerotic plaques at coronary ct angiography predicts major cardiac adverse events — The cafè-pie study," *International Journal of Cardiology*, vol. 215, pp. 325–331, 2016.

[11] E. Maffei, S. Seintun, C. Martini et al., "Prognostic value of computed tomography coronary angiography in patients with chest pain of suspected cardiac origin," *La Radiologia Medica*, vol. 116, no. 5, pp. 690–705, 2011.

[12] "CT coronary angiography in patients with suspected angina due to coronary heart disease (SCOT-HEART): an open-label, parallel-group, multicentre trial," *The Lancet*, vol. 385, no. 9985, pp. 2383–2391, 2015.

[13] E. Maffei, M. Midiri, V. Russo et al., "Rationale, design and methods of CTCA-PRORECAD (Computed Tomography Coronary Angiography Prognostic Registry for Coronary Artery Disease): a multicentre and multivendor registry," *La Radiologia Medica*, vol. 118, no. 4, pp. 591–607, 2013.

[14] D. Andreini, E. Martuscelli, A. I. Guaricci et al., "Clinical recommendations on Cardiac-CT in 2015: a position paper of the Working Group on Cardiac-CT and Nuclear Cardiology of the Italian Society of Cardiology," *Journal of Cardiovascular Medicine*, vol. 17, no. 2, pp. 73–84, 2016.

[15] L. J. Shaw, Y. Chandrashekar, and J. Narula, "Risk Detection Among Asymptomatic Patients With Diabetes: is It Time for a Varied Approach?" *JACC: Cardiovascular Imaging*, vol. 9, no. 11, pp. 1362–1365, 2016.

[16] C. S. Fox, S. H. Golden, C. Anderson et al., "Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American diabetes association," *Diabetes Care*, vol. 38, no. 9, pp. 1777–1803, 2015.
C. Lenfant, J. I. Cleeman, T. G. Ganiats et al., “Executive summary,” J. S. Rana, J. Y. Liu, H. H. Moffet, M. Jaffe, and A. J. Karter, J. J. Bax, S. E. Inzucchi, R. O. Bonow, J. D. Schuijf, M. R. Freeman, O. Vaccaro, L. E. Eberly, J. D. Neaton, L. Yang, G. Riccardi, and J. T. Y. Gorya, C. L. Leibson, P. J. Palmbe et al., “Coronary artery disease: a task force on diabetes, pre-diabetes, and cardiovascular disease of the European Society for Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD),” European Heart Journal, vol. 34, no. 39, pp. 3035–3087, 2013.

K. Gu, C. C. Cowie, and M. I. Harris, “Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971–1993,” Diabetes Care, vol. 21, no. 7, pp. 1138–1145, 1998.

S. M. Haffner, S. Lehto, T. Ronnemaa, K. Pyörälä, and M. Laakso, “Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction,” The New England Journal of Medicine, vol. 339, no. 4, pp. 229–234, 1998.

C. Lenfant, J. I. Cleeman, T. G. Ganiats et al., “Executive summary of the third report of the national cholesterol education program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel iii),” Journal of American Medical Association, vol. 285, no. 19, pp. 2486–2497, 2001.

S. Natarajan, Y. Liao, D. Sinha, G. Cao, D. L. McGee, and S. R. Lipsitz, “Sex differences in the effect of diabetes duration on coronary heart disease mortality,” JAMA Internal Medicine, vol. 165, no. 4, pp. 430–435, 2005.

F. B. Hu, M. J. Stampfer, C. G. Solomon et al., “The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up,” JAMA Internal Medicine, vol. 161, no. 14, pp. 1717–1723, 2001.

J. M. M. Evans, J. Wang, and A. D. Morris, “Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies,” British Medical Journal, vol. 324, no. 7343, pp. 939–942, 2002.

O. Vaccaro, L. E. Eberly, J. D. Neaton, L. Yang, G. Riccardi, and J. Stamler, “Impact of diabetes and previous myocardial infarction on long-term survival: 25-year mortality follow-up of primary screenees of the multiple risk factor intervention trial,” JAMA Internal Medicine, vol. 164, no. 13, pp. 1438–1443, 2004.

U. Bulugahapitiya, S. Sijambalapitiya, J. Sithole, and I. Idris, “Is diabetes a coronary risk equivalent? Systematic review and meta-analysis: original Article: Epidemiology,” Diabetic Medicine, vol. 26, no. 2, pp. 142–148, 2009.

J. S. Rana, J. Y. Liu, H. H. Moffet, M. Jaffe, and A. J. Karter, “Diabetes and Prior Coronary Heart Disease are Not Necessarily Risk Equivalent for Future Coronary Heart Disease Events,” Journal of General Internal Medicine, vol. 31, no. 4, pp. 387–393, 2016.

D. C. Goff Jr, D. M. Lloyd-Jones, and G. Bennett, “ACC/AHA guideline on the assessment of cardiovascular risk,” Journal of the American College of Cardiology, vol. 63, no. 25, pp. 2935–2959, 2013.

T. Y. Goraya, C. L. Leibson, P. J. Palumbo et al., “Coronary atherosclerosis in diabetes mellitus: a population-based autopsy study,” Journal of the American College of Cardiology, vol. 40, no. 5, pp. 946–953, 2002.

J. J. Bax, S. E. Inzucchi, R. O. Bonow, J. D. Schuijf, M. R. Freeman, and E. J. Barrett, “Cardiac imaging for risk stratification in diabetes,” Diabetes Care, vol. 30, no. 5, pp. 1295–1304, 2007.

G. Ambepitya, P. G. Kopelman, D. Ingram, M. Swash, P. G. Mills, and A. D. Timmis, “Exertional myocardial ischemia in diabetes: a quantitative analysis of anginal perceptual threshold and the influence of autonomic function,” Journal of the American College of Cardiology, vol. 15, no. 1, pp. 72–77, 1990.

S. M. Grundy, I. J. Benjamin, G. L. Burke et al., “Diabetes and cardiovascular disease: a statement for healthcare professionals from the american heart association,” Circulation, vol. 100, no. 10, pp. 1134–1146, 1999.

A. Elhendy, R. T. Van Domburg, D. Poldermans et al., “Safety and feasibility of dobutamine-atropine stress echocardiography for the diagnosis of coronary artery disease in diabetic patients unable to perform an exercise stress test,” Diabetes Care, vol. 21, no. 11, pp. 1797–1802, 1998.

S. G. Sawada, T. Ryan, M. J. Conley, B. C. Corya, H. Feigenbaum, and W. F. Armstrong, “Prognostic value of a normal exercise echocardiogram,” American Heart Journal, vol. 120, no. 1, pp. 49–55, 1990.

R. B. McCully, V. L. Roger, D. W. Mahoney et al., “Outcome after normal exercise echocardiography and predictors of subsequent cardiac events: follow-up of 1,325 patients,” Journal of the American College of Cardiology, vol. 31, no. 1, pp. 144–149, 1998.

T. G. Hennessy, M. B. Codd, G. Kane, C. McCarthy, H. A. McCann, and D. D. Sugrue, “Evaluation of patients with diabetes mellitus for coronary artery disease using dobutamine stress echocardiography,” Coronary Artery Disease, vol. 8, no. 3–4, pp. 171–174, 1997.

M. E. Griffin, K. Nikookam, M. M. Teh, H. McCann, N. M. O’Meara, and R. G. Firth, “Dobutamine stress echocardiography: false positive scans in proteinuric patients with type 1 diabetes mellitus at high risk of ischaemic heart disease,” Diabetic Medicine, vol. 15, no. 5, pp. 427–430, 1998.

M. Kamalesh, R. Matorin, and S. Sawada, “Prognostic value of a negative stress echocardiographic study in diabetic patients,” American Heart Journal, vol. 143, no. 1, pp. 163–168, 2002.

D. McGuire and C. Granger, “Diabetes and ischemic heart disease,” American Heart Journal, vol. 138, no. 4, pp. s366–s375, 1999.

L. Cortigiani, R. Bigi, R. Sicari, P. Landi, F. Bovenzi, and E. Picano, “Prognostic value of pharmacological stress echocardiography in diabetic and nondiabetic patients with known or suspected coronary artery disease,” Journal of the American College of Cardiology, vol. 47, no. 3, pp. 605–610, 2006.

N. Chaowalit, A. L. Arruda, R. B. McCully, K. R. Bailey, and P. A. Pellikka, “Dobutamine stress echocardiography in patients with diabetes mellitus: Enhanced prognostic prediction using a simple risk score,” Journal of the American College of Cardiology, vol. 47, no. 5, pp. 1029–1036, 2006.

F. B. Sozzi, A. Elhendy, J. R. T. C. Roelandt et al., “Prognostic value of dobutamine stress echocardiography in patients with diabetes,” Diabetes Care, vol. 26, no. 4, pp. 1074–1078, 2003.

S. Giri, L. J. Shaw, D. R. Murphy et al., “Impact of diabetes on the risk stratification using stress single-photon emission computed tomography myocardial perfusion imaging in patients with symptoms suggestive of coronary artery disease,” Circulation, vol. 105, no. 1, pp. 32–40, 2002.

M. Kamalesh, H. Feigenbaum, and S. Sawada, “Assessing Prognosis in Patients With Diabetes Mellitus-The Achilles’ Heel of Cardiac Stress Imaging Tests?” American Journal of Cardiology, vol. 99, no. 7, pp. 1016–1019, 2007.

J. M. Van Werkhoven, F. Cademartiri, S. Seitun et al., “Diabetes: prognostic value of CT coronary angiography - Comparison with a nondiabetic population,” Radiology, vol. 256, no. 1, pp. 83–92, 2010.
[45] J. Nadjiiri, J. Hausleiter, S. Deseve et al., "Prognostic value of coronary CT angiography in diabetic patients: a 5-year follow up study," *The International Journal of Cardiovascular Imaging*, vol. 32, no. 3, pp. 483–491, 2016.

[46] P. Blanke, C. Naoum, A. Ahmadi et al., "Long-Term Prognostic Utility of Coronary CT Angiography in Stable Patients With Diabetes Mellitus," *JACC: Cardiovascular Imaging*, vol. 9, no. 11, pp. 1280–1288, 2016.

[47] J. A. Rumberger, D. B. Simons, L. A. Fitzpatrick, P. F. Sheedy, and R. S. Schwartz, "Coronary artery calcium area by electron-beam computed tomography and coronary atherosclerotic plaque area: a histopathologic correlative study," *Circulation*, vol. 92, no. 8, pp. 2157–2162, 1995.

[48] Y. Arad, K. J. Goodman, M. Roth, D. Newstein, and A. D. Guerci, "Coronary calcification, coronary disease risk factors, C-reactive protein, and atherosclerotic cardiovascular disease events: the St. Francis heart study," *Journal of the American College of Cardiology*, vol. 46, no. 1, pp. 158–165, 2005.

[49] R. Detrano, A. D. Guerci, J. J. Carr et al., "Coronary calcium as a predictor of coronary events in four racial or ethnic groups," *The New England Journal of Medicine*, vol. 358, no. 13, pp. 1336–1345, 2008.

[50] E. Maffei, C. Martini, C. Tedeschi et al., "Diagnostic accuracy of 64-slice computed tomography coronary angiography in a large population of patients without revascularisation: registry data on the impact of calcium score," *La Radiologia Medica*, vol. 116, no. 7, pp. 1000–1013, 2011.

[51] M. F. Piepoli, A. W. Hoes, C. Brotons, R. F. Hobbs, and U. Corra, "Main messages for primary care from the 2016 European Guidelines on cardiovascular disease prevention in clinical practice," *European Journal of General Practice*, pp. 1–6, 2017.

[52] M. J. Wolk, S. R. Bailey, J. U. Doherty et al., "Multimodality appropriate use criteria for the detection and risk assessment of stable ischemic heart disease. American College of Cardiology Foundation Appropriate Use Criteria Task Force," *Journal of the American College of Cardiology*, vol. 63, no. 2, pp. 380–406, 2014.

[53] N. Wong, M. Sciammarella, and D. Polk, "The metabolic syndrome, diabetes and subclinical atherosclerosis assessed by coronary calcium," *ACC Current Journal Review*, vol. 12, no. 5, p. 41, 2003.

[54] D. A. Towler, M. Bidder, T. Latifi, T. Coleman, and C. F. Semenovich, "Diet-induced diabetes activates an osteogenic gene regulatory program in the aortas of low density lipoprotein receptor-deficient mice," *The Journal of Biological Chemistry*, vol. 273, no. 46, pp. 30427–30434, 1998.

[55] J. J. Bax, L. H. Young, R. L. Frye, R. O. Bonow, H. O. Steinberg, and E. J. Barrett, "Screening for coronary artery disease in patients with diabetes," *Diabetes Care*, vol. 30, no. 10, pp. 2729–2736, 2007.

[56] D. V. Anand, E. Lim, D. Hopkins et al., "Risk stratification in uncomplicated type 2 diabetes: prospective evaluation of the combined use of coronary artery calcium imaging and selective myocardial perfusion scintigraphy," *European Heart Journal*, vol. 27, no. 6, pp. 713–721, 2006.

[57] N. D. Wong, A. Rozanski, H. Gransar et al., "Metabolic syndrome and diabetes are associated with an increased likelihood of inducible myocardial ischemia among patients with subclinical atherosclerosis," *Diabetes Care*, vol. 28, no. 6, pp. 1445–1450, 2005.

[58] P. Raggi, B. Cool, C. Ratti, T. Q. Callister, and M. Budoff, "Progression of coronary artery calcium and occurrence of myocardial infarction in patients with and without diabetes mellitus," *Hypertension*, vol. 46, no. 1, pp. 238–243, 2005.

[59] J. Yeboah, R. Erbel, J. C. Delaney et al., "Development of a new diabetes risk prediction tool for incident coronary heart disease events: the Multi-Ethnic Study of Atherosclerosis and the Heinz Nixdorf Recall Study," *Atherosclerosis*, vol. 236, no. 2, pp. 411–417, 2014.

[60] M. J. Budoff, J. E. Hokanson, K. Nasir et al., "Progression of coronary artery calcium predicts all-cause mortality," *JACC: Cardiovascular Imaging*, vol. 3, no. 12, pp. 1229–1236, 2010.

[61] P. Raggi, L. J. Shaw, D. S. Berman, and T. Q. Callister, "Prognostic value of coronary artery calcium screening in subjects with and without diabetes," *Journal of the American College of Cardiology*, vol. 43, no. 9, pp. 1663–1669, 2004.

[62] R. A. Kronmal, R. L. McClelland, R. Detrano et al., "Risk factors for the progression of coronary artery calcification in asymptomatic subjects: results from the Multi-Ethnic Study of Atherosclerosis (MESA)," *Circulation*, vol. 115, no. 21, pp. 2722–2730, 2007.

[63] N. Lehmann, S. Mühlenkamp, A. A. Mahabadi et al., "Effect of smoking and other traditional risk factors on the onset of coronary artery calcification: results of the Heinz Nixdorf recall study," *Atherosclerosis*, vol. 232, no. 2, pp. 339–345, 2014.

[64] E. Maffei, G. Messalli, C. Martini et al., "Left and right ventricle receptor-deficient mice," *Diabetes Care*, vol. 27, no. 6, pp. 713–721, 2004.

[65] F. Cademartiri, E. Maffei, A. Palombo et al., "Clinical application of multi-detector computer tomography coronary angiography review," *Cardioangiologica*, vol. 57, no. 3, pp. 349–357, 2009.

[66] E. Maffei, S. Seitan, A. I. Guaricci, and F. Cademartiri, "Chest pain: Coronary CT in the ER," *British Journal of Radiology*, vol. 89, no. 1061, Article ID 20150954, 2016.

[67] J. Schulman-Marcus, R. Heo, H. Gransar et al., "Subclinical atherosclerosis detected by coronary computed tomographic angiography in Qatar: a comparison between Qatars and south Asian migrants," *The International Journal of Cardiovascular Imaging*, vol. 33, no. 6, pp. 927–935, 2017.

[68] S. Achenbach, D. Ropers, F. K. Pohle et al., "Detection of coronary artery stenoses using multi-detector CT with 16 x 0.75 mm slice thickness: Coronary CT in the ER," *European Heart Journal*, vol. 26, no. 19, pp. 1978–1986, 2005.

[69] A. I. Guaricci, E. Maffei, N. D. Brunetti et al., "Heart rate control with oral ivabradine in computed tomography coronary angiography: a randomized comparison of 7.5 mg vs 5 mg regimen," *European Heart Journal*, vol. 168, no. 1, pp. 362–368, 2013.

[70] A. I. Guaricci, J. D. Schuijf, F. Cademartiri et al., "Incremental value and safety of oral ivabradine for heart rate reduction in computed tomography coronary angiography," *International Journal of Cardiology*, vol. 156, no. 1, pp. 28–33, 2012.
and diagnostic accuracy of computed tomography coronary angiography," European Radiology, vol. 26, no. 1, pp. 147–156, 2016.

[73] T. Arcadi, E. Maffei, C. Martini et al., "Coronary CT angiography using iterative reconstruction vs. Filtered back projection: Evaluation of image quality," Acta Biomedica, vol. 86, no. 1, pp. 77–85, 2015.

[74] E. Maffei, C. Martini, S. De Crescenzo et al., "Low dose CT of the heart: a quantum leap into a new era of cardiovascular imaging," La Radiologia Medica, vol. 115, no. 8, pp. 1179–1207, 2010.

[75] G. Pontone, D. Andreini, A. Baggiano et al., "Functional relevance of coronary artery disease by cardiac magnetic resonance and cardiac computed tomography: myocardial perfusion and fractional flow reserve," BioMed Research International, vol. 2015, Article ID 297696, 2015.

[76] G. Pontone, D. Andreini, A. I. Guaricci et al., "Rationale and design of the PERFECTION (comparison between stress cardiac computed tomography PERFusion versus Fractional flow rEserve measured by Computed Tomography angiography in the evaluation of suspected cOrOvary artery disease) prospective study," Journal of Cardiovascular Computed Tomography, vol. 10, no. 4, pp. 330–334, 2016.

[77] A. I. Guaricci, "The frontier of the comprehensive information of the coronary plaque together with functional assessment is at the gates," in Proceedings of the Sep 1, vol. 24215, pp. 10–1016, 2017.

[78] G. Pontone, P. Carità, M. Verdeccchia et al., "Fractional flow reserve: lessons from PLATFORM and future perspectives," Minerva Cardioangioiogica, vol. 65, no. 3, pp. 235–251, 2017.

[79] G. Pontone, G. Muscogiuri, and D. Andreini, "The New Frontier of Cardiac Computed Tomography Angiography: fractional Flow Reserve and Stress Myocardial Perfusion," Current Treatment Options in Cardiovascular Medicine, vol. 18, no. 12, 2016.

[80] G. Pontone, E. Bertella, S. Musttaj et al., "Coronary artery disease: diagnostic accuracy of CT coronary angiography—a comparison of high and standard spatial resolution scanning," Radiology, vol. 271, no. 3, pp. 688–694, 2014.

[81] E. Maffei, S. Seitun, C. Martini et al., "Prognostic value of CT coronary angiography in diabetic and non-diabetic subjects with suspected CAD: importance of presenting symptoms," Insights Imaging, vol. 2, no. 1, pp. 25–38, 2011.

[82] G. Pundiutie, J. D. Schuijff, J. W. Jukema et al., "Noninvasive assessment of plaque characteristics with multislice computed tomography coronary angiography in symptomatic diabetic patients," Diabetes Care, vol. 30, no. 5, pp. 1113–1119, 2007.

[83] E. Maffei, S. Seitun, K. Nieman et al., "Assessment of coronary artery disease and calcified coronary plaque burden by computed tomography in patients with and without diabetes mellitus," European Radiology, vol. 21, no. 5, pp. 944–953, 2011.

[84] G. De Backer, E. Ambrosioni, K. Borch-Johnsen et al., "European guidelines on cardiovascular disease prevention in clinical practice: third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in clinical practice," European Heart Journal, vol. 24, no. 17, pp. 1601–1610, 2003.

[85] A. I. Guaricci and G. Pontone, "Toward a better selection of the asymptomatic patients worthy for screening of CAD: is it time for an update of the guidelines?" International Journal of Cardiology, vol. 234, p. 135, 2017.

[86] J. K. Min, T. M. Labounty, and M. J. Gomez, "Incremental prognostic value of coronary computed tomographic angiography over coronary artery calcium score for risk prediction of major adverse cardiac events in asymptomatic diabetic individuals," Atherosclerosis, vol. 232, pp. 298–304, 2014.

[87] D. A. Halon, M. Azenicot, R. Rubinshtein, B. Zafir, M. Y. Flugelman, and B. S. Lewis, "Coronary computed tomography (CT) angiography as a predictor of cardiac and noncardiac vascular events in asymptomatic type 2 diabetics: a 7-year population-based cohort study," Journal of the American Heart Association, vol. 5, no. 6, Article ID e003226, 2016.

[88] M. P. Ostrom, A. Gopal, N. Ahmadi et al., "Mortality Incidence and the Severity of Coronary Atherosclerosis Assessed by Computed Tomography Angiography," Journal of the American College of Cardiology, vol. 52, no. 16, pp. 1335–1343, 2008.

[89] M. Hadamitzky, B. FreiSMuth, T. Meyer et al., "Prognostic Value of Coronary Computed Tomographic Angiography for Prediction of Cardiac Events in Patients With Suspected Coronary Artery Disease," JACC: Cardiovascular Imaging, vol. 2, no. 4, pp. 404–411, 2009.

[90] J. D. Schuijff, J. J. Bax, J. W. Jukema et al., "Noninvasive angiography and assessment of left ventricular function using multislice computed tomography in patients with type 2 diabetes," Diabetes Care, vol. 27, no. 12, pp. 2905–2910, 2004.

[91] W. B. Meijboom, M. E. Meijls, J. D. Schuijff et al., "Diagnostic accuracy of 64-slice computed tomography coronary angiography: a prospective, multicenter, multivendor study," Journal of the American College of Cardiology, vol. 52, no. 25, pp. 2135–2144, 2008.

[92] J. J. Kim, B.-H. Hwang, I. J. Choi et al., "Impact of diabetes duration on the extent and severity of coronary atheroma burden and long-term clinical outcome in asymptomatic type 2 diabetic patients: evaluation by coronary CT angiography," European Heart Journal—Cardiovascular Imaging, vol. 16, no. 10, pp. 1065–1073, 2015.

[93] J. B. Muhlestein, D. L. Lappe, J. A. C. Lima et al., "Effect of screening for coronary artery disease using CT angiography on mortality and cardiac events in high-risk patients with diabetes: the FACTOR-64 randomized clinical trial," Journal of the American Medical Association, vol. 312, no. 21, pp. 2234–2243, 2014.

[94] S. H. Kang, G.-M. Park, S.-W. Lee et al., "Long-Term Prognostic Value of Coronary CT Angiography in Asymptomatic Type 2 Diabetes Mellitus," JACC: Cardiovascular Imaging, vol. 9, no. 11, pp. 1292–1300, 2016.

[95] C. Celeng, P. Maurovich-Horvat, B. B. Ghoshshajra, B. Merkely, T. Leiner, and R. A. P. Taks, "Prognostic value of coronary computed tomography angiography in patients with diabetes: a meta-analysis," Diabetes Care, vol. 39, no. 7, pp. 1274–1280, 2016.

[96] S. Motoyama, H. Ito, M. Sarai et al., "Plaque characterization by coronary computed tomography angiography and the likelihood of acute coronary events in mid-term follow-up," Journal of the American College of Cardiology, vol. 66, no. 4, pp. 337–346, 2015.

[97] A. I. Guaricci, T. Arcadi, N. D. Brunetti et al., "Carotid intima media thickness and coronary atherosclerosis linkage in symptomatic intermediate risk patients evaluated by coronary computed tomography angiography," International Journal of Cardiology, vol. 176, no. 3, pp. 988–993, 2014.

[98] A. I. Guaricci, G. Pontone, and L. Fusini, "Additional value of inflammatory biomarkers and carotid artery disease in prediction of significant coronary artery disease as assessed by coronary computed tomography angiography," European Heart Journal—Cardiovascular Imaging, vol. 14, no. Oct 14, 2016.
[99] J. L. Rosenzweig, E. Ferrannini, S. M. Grundy et al., “Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline,” The Journal of Clinical Endocrinology & Metabolism, vol. 93, no. 10, pp. 3671–3689, 2008.

[100] R. J. Stevens, V. Kothari, A. I. Adler, I. M. Stratton, and R. R. Holman, “The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56),” Clinical Science, vol. 101, no. 6, pp. 671–679, 2001.

[101] J. Cederholm, K. Eeg-Olofsson, B. Eliasson, B. Zethelius, P. M. Nilsson, and S. Gudbjörnsdottir, “Risk prediction of cardiovascular disease in type 2 diabetes,” Diabetes Care, vol. 31, no. 10, pp. 2038–2043, 2008.

[102] D. V. Anand, E. Lim, A. Lahiri, and J. J. Bax, “The role of non-invasive imaging in the risk stratification of asymptomatic diabetic subjects,” European Heart Journal, vol. 27, no. 8, pp. 905–912, 2006.

[103] A. C. Dimitriu-Leen, A. J. H. A. Scholte, A. R. Van Rosendaal et al., “Value of coronary computed tomography angiography in tailoring aspirin therapy for primary prevention of atherosclerotic events in patients at high risk with diabetes mellitus,” American Journal of Cardiology, vol. 117, no. 6, pp. 887–893, 2016.

[104] G. Davì and C. Patrono, “Platelet activation and atherothrombosis,” The New England Journal of Medicine, vol. 357, no. 24, pp. 2482–2494, 2007.

[105] M. G. Silverman, M. J. Blaha, M. J. Budoff et al., “Potential implications of coronary artery calcium testing for guiding aspirin use among asymptomatic individuals with diabetes,” Diabetes Care, vol. 35, no. 3, pp. 624–626, 2012.

[106] J. Belch, A. MacCuish, I. Campbell et al., “The Prevention of Progression of Arterial Disease and Diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease,” British Medical Journal, vol. 337, article a1840, 10 pages, 2008.

[107] H. Ogawa, M. Nakayama, T. Morimoto et al., “Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial,” Journal of the American Medical Association, vol. 300, no. 18, pp. 2134–2141, 2008.

[108] F. C. Taylor, M. Huffman, and S. Ebrahim, “Statin therapy for primary prevention of cardiovascular disease,” The Journal of the American Medical Association, vol. 310, no. 22, pp. 2451-2452, 2013.